Assessment of the effect of ramipril therapy on direct health care costs for first and recurrent strokes in high-risk cardiovascular patients using data from the Heart Outcomes Prevention Evaluation (HOPE) Study

Clinical Therapeutics

Volumn 25, Issue 4, 2003, Pages 1248-1261

  Carroll, Cathryn A ^a   Coen, Michael M ^b   Rymer, Marilyn M ^b,c  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b Saint Luke's Health System Missouri   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

ACE inhibitor; Cost; Economics; Prevention; Ramipril; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; RAMIPRIL;

ADULT; AGE; ARTICLE; CALCULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION MAKING; DRUG COST; DRUG EFFECT; DRUG USE; ECONOMIC ASPECT; FOLLOW UP; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; OUTCOMES RESEARCH; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; STROKE;

EID: 0038408696     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80081-4     Document Type: Article

References (22)

1. American Heart Association. Heart Disease and Stroke Statistics - 2003 Update. Dallas, Tex: American Heart Association; 2003.
2. Elixhauser A, Yu K, Steiner C, Bierman AS. Hospitalization in the United States, 1997. Rockville, Md: Agency for Healthcare Research and Quality; 2000. AHRQ Publication no. 00-0031.
3. Samsa GP, Bian J, Lipscomb J, Matchar DB. Epidemiology of recurrent cerebral infarction: A Medicare claims-based comparison of first and recurrent strokes on 2-year survival and cost. Stroke. 1999;30:338-349.
4. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
5. US Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Washington, DC: US Department of Labor; 2001.
6. Drug Topics Red Book. Montvale, NJ: Medical Economics Co, Inc; 1995.
7. Drug Topics Red Book. Montvale, NJ: Medical Economics Co, Inc; 1996.
8. Drug Topics Red Book. Montvale, NJ: Medical Economics Co, Inc; 1997.
9. Drug Topics Red Book. Montvale, NJ: Medical Economics Co, Inc; 1998.
10. Shah H, Gondek K. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: A cost-effectiveness analysis. Clin Ther. 2000;22:362-370.
11. Riviere M, Wang S, Leclerc C, et al. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada. CMAJ. 1997;156:991-997.
12. Chambers M, Hutton J, Gladman J. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole. PharmacoEconomics. 1999;16:577-593.
13. Stier CT Jr, Benter IF, Ahmad S, et al. Enalapril prevents stroke and kidney dysfunction in salt-loaded stroke-prone spontaneously hypertensive rats. Hypertension. 1989;13:115-121.
14. Richer C, Fornes P, Vacher E, et al, Trandolapril's protective effects in stroke-prone spontaneously hypertensive rats persist long after treatment withdrawal. Am J Cardiol. 1994;73:26C-35C.
15. Biagini G, Zoli M, Torri C, et al. Protective effects of delapril, indapamide and their combination chronically administered to stroke-prone spontaneously hypertensive rats fed a high-sodium diet. Clin Sci (Lond). 1997;93:401-411.
16. Blezer EL, Nicolay K, Bar D, et al. Enalapril prevents imminent and reduces manifest cerebral edema in stroke-prone hypertensive rats. Stroke. 1998;29:1671-1678.
17. Francis, GS. ACE inhibition in cardiovascular disease. N Engl J Med. 2000;342:201-202. Editorial.
18. Nawarskas JJ, Spinler SA. Update on the interaction between aspinn and angiotensin-converting enzyme inhibitors. Pharmacotherapy. 2000;20:698-710.
19. Frank RG. Prescription drug prices: Why do some pay more than others do? Health Aff (Millwood). 2001;20:115-128.
20. Taylor TN. The medical economics of stroke. Drugs. 1997;54(Suppl 3):51-58.
21. Taylor TN, Davis PH, Torner JC, et al. Lifetime cost of stroke in the United States. Stroke. 1996;27:1459-1466.
22. Holloway RG, Witter DM Jr, Lawton KB, et al. Inpatient costs of specific cerebrovascular events at five academic medical centers. Neurology. 1996;46:854-860.